Lower Than Expected R&D Expenses Drive 3Q EPS Beat for BioBlast Pharma (ORPN); Oppenheimer Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Roth Capital Bullish on Recent BioBlast Pharma (ORPN) Hires; Reaffirms at 'Buy'
November 17, 2015 9:00 AM ESTRoth Capital reaffirms BioBlast Pharma (Nasdaq: ORPN) with a Buy rating and $26 price target after ORPN announced the appointment of three new senior executives to its leadership team: Warren Wasiewski, M.D. as Chief Medical Officer and Vice President, Research & Development, Leigh Cherry as Vice... More
BioBlast Pharma (ORPN) Tops Q3 EPS by 4c
November 17, 2015 8:03 AM ESTBioBlast Pharma (NASDAQ: ORPN) reported Q3 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29).
BioBlast ended the third quarter of 2015 with $23.1 million in cash and short-term bank deposits, total quarterly expenses were $3.6 million whereas total quarterly expenses excluding stock based compensation were $3.0 million.
On... More
